Signal Work

Identifying sources of potential harm to patients is UMC’s highest priority. Detecting and communicating signals of such harm lies at the heart of pharmacovigilance.

Identifying safety signals

Signal work aims to identify and describe suspected harm to patients caused by the medicines they use. The evidence comes primarily in the form of spontaneous reports from health professionals across the world, from pharmaceutical companies, and some from patients. Signal work is a core UMC activity.

What is a signal?

Signal detection 

With the unique resource of VigiBase and by performing signal detection in parallel with method development, UMC is well-positioned to discover new and important signals.

Signal detection at UMC

Clinical assessment 

Signals of interest are further evaluated to identify the need for additional data collection, risk mitigation or minimisation activities, or regulatory action.

Clinical assessment at UMC 

Communicating signals

UMC regularly communicates its signals to national pharmacovigilance centres around the world, or publicly in the WHO Pharmaceuticals Newsletter or a scientific journal.

Read more  Signal library